4//SEC Filing
Soffer Gad 4
Accession 0001415889-25-024443
CIK 0001691082other
Filed
Sep 11, 8:00 PM ET
Accepted
Sep 12, 6:25 PM ET
Size
10.8 KB
Accession
0001415889-25-024443
Insider Transaction Report
Form 4
Soffer Gad
Chief Business Officer
Transactions
- Award
Employee Stock Option (Right to Buy)
2025-09-10+229,860→ 229,860 totalExercise: $15.00Exp: 2035-09-09→ Common Stock (229,860 underlying) - Award
Employee Stock Option (Right to Buy)
2025-09-10+26,893→ 26,893 totalExercise: $15.00Exp: 2035-02-10→ Common Stock (26,893 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2025-09-10−26,893→ 0 totalExercise: $41.84Exp: 2035-02-10→ Common Stock (26,893 underlying)
Footnotes (3)
- [F1]One fourth (1/4) of the shares subject to the option award shall vest on February 5, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
- [F2]The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect.
- [F3]One fourth (1/4) of the shares subject to the option award shall vest on September 10, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
Documents
Issuer
LB PHARMACEUTICALS INC
CIK 0001691082
Entity typeother
Related Parties
1- filerCIK 0001612090
Filing Metadata
- Form type
- 4
- Filed
- Sep 11, 8:00 PM ET
- Accepted
- Sep 12, 6:25 PM ET
- Size
- 10.8 KB